Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from Innovate UK to support the Phase II development of AT247, its ultra-rapid acting insulin product candidate which is based on Arecor’s proprietary Arestat™ technology platform.
Sarah Howell, Chief Executive Officer of Arecor, said: " We are proud that Innovate UK has, through their thorough technical and commercial review process, chosen to invest in our research from across the very best of British science. Diabetes remains a significant and growing health problem throughout the world. AT247, the lead product from our pipeline of next generation rapid insulins is focused on transforming the lives of people living with Type 1 diabetes through its potential to enable greater glucose control. This control is critical in helping patients to avoid hyper- and hypo-glycaemia events, improve time in range and reduce overall disease complications. The substantial grant we are announcing today provides additional non-dilutive funding to support and accelerate AT247’s Phase II development.”
Dr Thomas Pieber, PI for the Phase II study at Medical University of Graz said: “AT247 is a very promising candidate in the pursuit for next generation insulins designed to improve postprandial glycaemic control and flexibility of insulin dosing. The Phase II development programme will build on the early clinical evidence that AT247 has highly favourable pharmacokinetic properties(1) and may facilitate a fully closed loop artificial pancreas, a potentially life changing treatment option for people living with diabetes."
AT247, a novel proprietary formulation of insulin, has been designed to accelerate insulin absorption, post injection, to achieve more effective and controlled management of blood glucose levels. The development programme, supported by the grant, will include a Phase II clinical trial to compare the glycaemic control, safety and tolerability of AT247 with Fiasp® when administered by insulin pump over an extended period. Continuous glucose monitoring will allow the assessment of time spent with blood glucose level in a healthy range, the control of which is crucial for avoiding episodes of hyper- and hypo- glycaemia and delivering positive long term health outcomes for people with Type 1 Diabetes. This Phase II clinical trial is expected to commence in H1 2022 and is part of an extensive development programme designed to demonstrate the benefits of AT247 as a potentially best-in-class ultra-rapid acting insulin.